MEA Zika Virus Vaccines Market Report

MEA Zika Virus Vaccines Market Size

The Middle East & Africa Zika virus vaccines market size was valued at USD 1.51 billion in 2024 and is estimated to reach USD 2.60 billion by 2033 from USD 1.60 billion in 2025, registering a CAGR of 6.24% from 2025 to 2033.

Government initiatives, a large population of the patients, an increase in healthcare expenditure, and disposable income are the factors driving the Middle East and Africa (MEA) Zika virus vaccines market. Reimbursement, favorable government policies, close attention towards pregnant women, rise in incidences of the Zika virus, and advanced technology developments in health care are also driving the MEA Zika virus vaccine market. An increase in understanding of Zika virus infection and investments made by the private companies drives the regional MEA Zika virus vaccine market.

World Health Organization (WHO announced that the Zika virus would not be a widespread ailment in the coming years, which is the factor restraining the regional vaccines market. The requirement of the massive number of investments in the development of vaccines may also suppress the growth of the MEA Zika Virus Vaccines Market. Lack of awareness is projected to hinder the growth of this business further.

The opportunities the market offers are the need to prevent the virus, immunization of vaccines, and treatment for Zika linked congenital disabilities, i.e., newborn babies who are diagnosed with this virus, and the further spread of Zika virus infection. The factors mentioned in the challenges have resulted in the pharmaceutical organizations' interest to invest and capitalize on the growth challenges. 

The crucial challenges that come in face to face with the healthcare and government in the regions like the Middle East & Africa are spreading the Zika virus. The deficiency of preventive and effective medical solutions towards the treatment may hinder the expansion of this regional market in the coming years. To overcome these challenges, the government and other research institutes are motivating and supporting the pharmaceutical regions to invest, funds, and providing infrastructure and outsourcing of labor. The in-depth analysis provides an insight underlying the growth and challenges.

REGIONAL ANALYSIS

Regionally, Middle East and Africa have the second-largest share in terms of revenue due to countries like the USA, China, and the UK are investing in the region. This increased financial revenue will aid the healthcare sectors in this region.

KEY MARKET PLAYERS

Companies playing a key role in the MEA Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline plc.., Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.

MARKET SEGMENTATION

This research report on the MEA Zika Virus Vaccines Market has been segmented & sub-segmented into the following categories:

By Type

• Therapeutic Vaccines
• Preventive Vaccines

By End-User

• Hospitals
• Clinics
• Research Institutes
• Others

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA